ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) today announced that it presented preclinical data on its lead bispecific ADAPTIRTM (Modular Protein Technology) therapeutic, ES414, at the 5th Annual Protein and Antibody Engineering Summit (PEGS) in Lisbon, Portugal. The ES414 molecule was constructed using Emergent’s ADAPTIR technology platform and is being developed as a potential therapeutic for metastatic castration-resistant prostate cancer (mCRPC).
Help employers find you! Check out all the jobs and post your resume.
